acut
respiratori
distress
syndrom
ard
condit
character
pulmonari
inflamm
diffus
pulmonari
edema
refractori
hypoxemia
may
complic
pneumonia
sepsi
trauma
lead
multiorgan
failur
ard
mortal
approxim
depend
sever
disord
treatment
ard
still
reli
manag
underli
diseas
support
care
sinc
pharmacolog
intervent
target
key
pathophysiolog
determin
ard
still
avail
key
pathophysiolog
event
ard
uncontrol
inflammatori
respons
result
injuri
endothelialalveolar
barrier
increas
pulmonari
vascular
leakag
endogen
product
type
ifn
ifn
beta
alpha
outmost
import
fight
viral
bacteri
infect
sinc
upregul
cluster
differenti
express
endothelium
cell
enzym
control
endotheli
barrier
function
leucocyt
recruit
site
inflamm
via
product
adenosin
highli
antiinflammatori
substanc
cardioprotect
neuroprotect
vasodilatori
angiogen
properti
phase
ii
trial
show
upregul
via
intraven
administr
recombin
human
interferon
associ
reduct
mortal
ard
follow
placebocontrol
phase
iii
trial
interest
show
intraven
recombin
human
interferon
improv
outcom
patient
ard
howev
studi
show
use
corticosteroid
baselin
higher
posthoc
analys
reveal
statist
signific
interact
baselin
corticosteroid
treatment
group
present
studi
set
test
hypothesi
lack
efficaci
recombin
human
ifn
patient
ard
could
relat
interfer
glucocorticoid
ifn
administr
prevent
upregul
accordingli
first
perform
posthoc
propensitymatch
analysi
interest
trial
clincaltrialsgov
identifi
second
investig
effect
glucocorticoid
ifn
signal
upregul
express
use
human
lung
organ
cultur
human
pulmonari
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
endotheli
cell
ex
vivo
although
preclin
evid
steroid
block
endogen
ifn
signal
work
put
context
critic
care
commun
treat
ard
interest
trial
multicent
random
doubleblind
parallelgroup
trial
conduct
intens
care
unit
european
countri
decemb
decemb
includ
adult
moder
sever
ard
patient
random
receiv
intraven
inject
ifn
patient
placebo
patient
analysi
explor
possibl
interact
glucocorticoid
ifn
present
kaplanmey
surviv
curv
day
ifn
treat
patient
without
concomit
glucocorticoid
addit
perform
propens
score
repres
risk
receiv
glucocorticoid
random
match
ifn
group
obtain
reliabl
estim
confound
effect
glucocorticoid
ifn
treatment
propens
score
calcul
base
logist
regress
model
includ
age
gender
ard
sever
acut
physiolog
chronic
health
evalu
apach
ii
sequenti
organ
failur
assess
sofa
score
propens
score
includ
final
logist
regress
model
evalu
independ
factor
relat
mortal
furthermor
present
comparison
propensitymatch
patient
group
present
associ
mortal
odd
ratio
confid
interv
ci
human
lung
experi
repeat
previous
present
bellingan
et
al
except
hydrocortison
treatment
ad
indic
brief
lung
specimen
differ
individu
obtain
postsurg
resect
lung
tissu
typic
cancer
resect
lung
section
lung
region
normal
macroand
microscop
appear
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
use
permiss
ethic
author
turku
univers
hospit
finland
sever
small
piec
cut
sampl
pieceswellcondit
cultur
day
well
plate
contain
ml
rpmi
medium
supplement
fetal
calf
serum
mm
lglutamin
uml
penicillin
streptomycin
ifn
beta
uiml
drug
substanc
faron
pharmaceut
placebo
without
hydrocortison
solucortef
pfizer
lyophil
form
drug
substanc
cultur
piec
well
collect
frozen
oct
day
human
pulmonari
endotheli
cell
promocel
plate
cellswel
endotheli
cell
growth
mv
medium
promocel
supplement
mix
promocel
penicillinstreptomycin
well
ibidi
plate
falcon
day
hydrocortison
solucortef
pfizer
ad
half
well
day
ifn
beta
faron
rebif
merck
placebo
incub
continu
one
day
two
differ
lot
cell
use
six
thick
section
cut
cultur
lung
piec
fix
aceton
thereaft
section
stain
use
monoclon
antibodi
neg
class
match
control
antibodi
follow
alexa
conjug
goat
antimous
igg
invitrogen
hrp
conjug
antimous
igg
dako
diaminobenzidin
use
chromogen
peroxidas
stain
number
posit
vessel
count
use
stain
section
averag
fieldssampl
count
magnif
use
fluoresc
microscop
olympu
human
pulmonari
cell
wash
phosphat
buffer
salin
pb
fix
paraformaldehyd
follow
treatment
glycin
pb
thereaft
cell
incub
min
pb
contain
tritonx
stain
use
antibodi
ls
bio
rabbit
ig
neg
control
second
stage
antibodi
fitcantirabbit
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
igg
sigma
signal
intensifi
use
alexa
fluor
antifitc
sampl
mount
mowiol
contain
dabco
sigma
nuclear
cytoplasm
fraction
human
pulmonari
endotheli
cell
without
ifn
hydrocortison
isol
use
triton
centrifug
rpm
hydrocortison
ad
one
day
ifn
pulmonari
endotheli
cell
lyse
two
hour
addit
ifn
protein
concentr
sampl
determin
bca
protein
assay
kit
pierc
amount
protein
load
gel
sdspage
blot
perform
use
biorad
blot
system
transblot
turbo
transfer
system
block
nonspecif
bind
nitrocellulos
transfer
membran
perform
bovin
serum
albumin
tween
tri
buffer
salin
membran
blot
ls
bio
follow
hrpconjug
antirabbit
igg
dako
gapdh
load
control
cytoplasm
protein
detect
antigapdh
antibodi
hytest
ltd
follow
donkey
antimous
igg
licor
histon
load
control
nuclear
protein
antihiston
antibodi
cell
signal
follow
goat
antirabbit
igg
licor
millipor
immobilon
western
use
signal
detect
human
pulmonari
endotheli
cell
treat
describ
gel
analys
collect
store
rnaprotect
cell
reagent
qiagen
hilden
germani
follow
rna
extract
nucleospin
rna
kit
machereynagel
dueren
germani
accord
manufactur
protocol
qpcr
assay
convers
rna
cdna
done
superscript
vilo
cdna
synthesi
kit
thermo
fisher
scientif
espoo
finland
follow
qpcr
use
taqman
gene
express
assay
thermo
fisher
scientif
espoo
finland
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
gapdh
control
gene
reaction
run
use
appli
biosystem
quant
studio
realtim
pcr
system
thermo
fisher
scientif
target
mrna
level
normalis
gapdh
fold
chang
rel
express
appropri
unstimul
control
calcul
use
appli
analysi
modul
thermo
fisher
cloud
comput
platform
thermo
fisher
scientif
espoo
finland
seventyeight
patient
includ
ifn
treatment
arm
interest
trial
receiv
glucocorticoid
studi
period
random
treatment
treatment
onward
report
reason
administ
system
glucocorticoid
shock
antiinflammatori
ard
fibrosi
immunosuppress
posttranspl
adren
insuffi
pulmonari
obstruct
commonli
use
glucocorticoid
hydrocortison
per
day
methylprednisolon
per
day
use
togeth
ifn
patient
receiv
dexamethason
ifn
lymphoma
mortal
patient
receiv
glucocorticoid
ifn
compar
patient
receiv
ifn
alon
tabl
kaplanmei
curv
ifn
treatment
arm
adjust
ard
sever
divid
accord
overlap
use
glucocorticoid
ifn
treatment
demonstr
significantli
increas
mortal
glucocorticoid
use
p
figur
patient
receiv
glucocorticoid
sever
ill
accord
sofa
apach
ii
score
signific
differ
vasopressor
use
pf
ratio
ventil
set
tabl
demograph
data
propensitymatch
patient
glucocorticoid
vs
glucocorticoid
present
tabl
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
posthoc
propensitymatch
analysi
ifn
arm
baselin
system
glucocorticoid
treatment
independ
associ
mortal
ci
p
accord
logist
regress
propens
match
analysi
perform
use
exact
match
precis
propens
unit
pair
patient
receiv
receiv
glucocorticoid
among
patient
increas
mortal
ci
baselin
system
glucocorticoid
treatment
ci
initi
glucocorticoid
treatment
receiv
ifn
tabl
glucocorticoid
treatment
ifn
treatment
onward
associ
increas
mortal
test
possibl
inhibitori
effect
hydrocortison
hc
ifn
induc
upregul
blood
vessel
cultur
histolog
normal
lung
tissu
presenc
ifn
without
hc
day
time
cours
two
differ
formul
ifn
use
lyophil
product
use
phase
iii
trial
drug
substanc
ds
lyophil
ifn
appli
cultur
medium
express
upregul
comparison
cultur
without
ifn
pharmaceut
form
ifn
induc
similar
level
upregul
howev
presenc
hydrocortison
upregul
inhibit
figur
b
ifn
signal
via
receptor
lead
format
heterotrimer
transcript
complex
contain
enter
nucleu
bind
ifn
beta
respons
element
sever
gene
assembl
dna
main
target
glucocorticoid
type
interferon
pathway
pulmonari
epithelium
test
whether
also
true
endothelium
primari
human
pulmonari
endotheli
cell
cultur
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
presenc
ifn
without
hc
cultur
medium
baselin
control
express
analyz
immunofluoresc
stain
expect
ifn
induc
transloc
nucleu
reduc
hc
treatment
fig
confirm
find
isol
nuclear
cytoplasm
compart
pulmonari
endotheli
cell
analyz
separ
sdspage
subsequ
immunoblot
fig
similarli
also
analys
show
transloc
nucleu
subsequ
ifn
treatment
could
reduc
hc
addit
hc
treatment
decreas
mrna
synthesi
measur
qpcr
fig
also
seen
protein
level
fig
contrast
hc
decreas
mrna
synthesi
ifn
alfabeta
receptor
subunit
mrna
synthesi
ifn
alfabeta
receptor
subunit
increas
respect
subsequ
hc
addit
clinic
experiment
data
suggest
associ
glucocorticoid
treatment
increas
mortal
might
relat
hydrocortisoneinduc
inhibit
upregul
human
lung
tissu
ifn
beta
depend
signal
pathway
pulmonari
endotheli
cell
use
steroid
patient
ard
gener
great
controversi
earli
studi
suggest
clinic
benefit
subsequ
studi
support
routin
use
steroid
earli
persist
ard
find
consist
contemporari
bayesean
metaanalysi
show
steroid
ineffectiveharm
ard
contradict
result
recent
rct
dexamethason
ard
patient
notabl
dexamethason
studi
villar
et
al
exclud
patient
alreadi
receiv
steroid
enrol
possibl
explan
inconsist
find
may
lay
origin
ard
viral
vs
genet
factor
use
differ
corticosteroid
use
ifn
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
beta
treatment
interest
trial
may
shed
light
complex
issu
hydrocortison
methylprednisolon
use
major
patient
alreadi
receiv
prior
receiv
ifn
increas
extracellular
adenosin
activ
epitheli
endotheli
cell
one
biolog
target
ifn
adenosin
one
physiolog
regul
endotheli
cell
permeabl
acceler
alveolar
fluid
reabsorpt
inhibit
leukocyt
recruit
although
previou
studi
shown
steroid
inhibit
effect
type
ifn
signal
asthmat
epithelium
use
corticosteroid
unexpectedli
high
placebo
ifn
group
interest
studi
therefor
present
analys
focus
possibl
interact
steroid
ifn
human
pulmonari
endothelium
express
key
enzym
local
adenosin
product
vascular
integr
found
signific
increas
risk
death
baselin
system
glucocorticoid
treatment
glucocorticoid
use
overlap
ifn
treatment
tabl
sinc
type
ifn
ifn
beta
alpha
endogen
produc
utmost
import
fight
infect
bacteri
viral
observ
may
explain
fact
glucocorticoid
use
patient
viru
trigger
ard
associ
increas
risk
death
line
interpret
other
shown
use
recombin
human
ifn
beta
inhibit
sar
viru
replic
antivir
potenti
even
infect
furthermor
use
ifn
alpha
associ
lower
mortal
previou
mer
epidem
ifn
fail
repeat
result
larger
cohort
mer
patient
howev
patient
receiv
subcutan
ifn
beta
give
limit
direct
drug
exposur
lung
endotheli
cell
importantli
patient
receiv
corticosteroid
base
find
prevent
ifn
beta
signal
earlier
report
shown
glucocorticoid
target
type
interferon
signal
pathway
inhibit
assembl
complex
mous
macrophag
human
epitheli
cell
pulmonari
endotheli
cell
cultur
observ
use
hydrocortison
one
day
reduc
mrna
synthesi
compon
complex
effect
due
downregul
ifn
alphabeta
receptor
moreov
wit
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
inhibit
transloc
nucleu
requir
trigger
ifn
beta
respons
gene
essenti
type
ifn
respons
defici
lead
sever
lifethreaten
condit
common
viral
infect
type
interferon
respons
gene
http
wwwinterferomeorginterferomesitedbstatjspx
effect
glucocorticoid
extens
alreadi
taken
target
type
ifn
signal
pathway
account
addit
glucocorticoid
inhibit
product
secret
type
ifn
use
hydrocortison
ex
vivo
experi
commonli
use
clinic
practic
although
glucocorticoid
differ
potenc
act
via
glucocorticoid
receptor
affect
signal
pathway
thu
obtain
effect
expect
gener
glucocorticoid
use
treat
ard
patient
complex
also
drive
express
envis
also
express
decreas
due
glucocorticoid
use
addit
mediat
transactiv
gene
may
also
impact
glucocorticoid
induc
phosphoryl
normal
interact
requir
mediat
gene
transactiv
earlier
data
togeth
ex
vivo
result
util
hydrocortison
togeth
ifn
demonstr
glucocorticoid
interfer
product
sinc
gene
encod
contain
respons
element
interferon
isr
hypoxia
hre
conclus
found
hydrocortison
inhibit
upregul
human
lung
tissu
ifn
beta
depend
signal
pathway
pulmonari
endotheli
cell
import
regul
vascular
integr
especi
need
condit
ard
therefor
experiment
find
combin
propensitymatch
analysi
ifn
treat
patient
intererst
trial
provid
mechanist
evid
harm
effect
glucocorticoid
ifn
respons
human
lung
data
provid
rational
contraind
use
steroid
patient
ard
viral
origin
ifn
respons
requir
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
declar
ethic
approv
consent
particip
procedur
perform
studi
involv
human
particip
origin
interest
trial
clincaltrialsgov
identifi
accord
ethic
standard
institut
andor
nation
research
committe
helsinki
declar
avail
data
materi
public
data
novel
reagent
antibodi
made
avail
other
reason
request
correspond
author
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
figur
hydrocortison
hc
blunt
ifn
beta
induc
upregul
lung
vasculatur
signal
pathway
pulmonari
endotheli
cell
immunohistochem
stain
brown
lung
tissu
incub
presenc
ifn
beta
without
hc
day
indic
baselin
express
fresh
lung
tissu
b
quantif
posit
vesselsmm
sampl
incub
presenc
two
differ
ifn
formul
circl
day
day
ds
triangl
data
point
mark
individu
dot
line
repres
placebo
induc
level
express
statist
signific
analyz
use
mann
whitney
test
scale
bar
c
immunofluoresc
stain
primari
human
pulmonari
endotheli
cell
ifn
beta
treatment
without
hc
show
mark
inhibit
nuclear
transloc
hc
repres
result
three
independ
one
similar
result
immunoblot
cytosol
nuclear
fraction
pulmonari
endotheli
cell
ifn
hc
demonstr
decreas
signal
transloc
specif
band
indic
arrow
repres
blot
five
independ
analys
compar
result
gapdh
histon
load
control
cytoplasm
nuclear
fraction
respect
e
qpcr
result
two
independ
experi
demonstr
decreas
ifn
trigger
mrna
synthesi
hc
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
